Varenicline

A Novel Pharmacotherapy for Smoking Cessation

Carlos Jiménez-Ruiz, Ivan Berlin and Thomas Hering

Supplementary Material

This supplementary material contains the table referred to in the full version of this article, which can be found at http://drugs.adisonline.com.
Adverse events occurring in placebo-controlled phase II and III trials of varenicline

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Abnormal dreams</th>
<th>Constipation</th>
<th>Dry mouth</th>
<th>Dryness in mouth</th>
<th>Dysgeusia</th>
<th>Dysphagia in swallowing</th>
<th>Dysphoria</th>
<th>Elevated blood pressure</th>
<th>Increased intracranial pressure</th>
<th>Insomnia</th>
<th>Influenza</th>
<th>Irritability</th>
<th>Respiratory tract infection</th>
<th>Sore throat</th>
<th>Somnolence</th>
<th>Spasms</th>
<th>Sinusitis</th>
<th>Anxiety</th>
<th>Apnoea</th>
<th>Asthenia</th>
<th>Back pain</th>
<th>Weight increase</th>
<th>Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gonzales et al. [33]</td>
<td>Varenicline 1 mg bid</td>
<td>349</td>
<td>28.1</td>
<td>15.5</td>
<td>14.0</td>
<td>10.3</td>
<td>6.0</td>
<td>5.4</td>
<td>5.7</td>
<td>5.7</td>
<td>6.0</td>
<td>6.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bupropion SR 150 mg bid</td>
<td>329</td>
<td>12.5</td>
<td>14.3</td>
<td>21.9</td>
<td>5.5</td>
<td>5.8</td>
<td>7.0</td>
<td>4.3</td>
<td>4.0</td>
<td>5.2</td>
<td>8.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>344</td>
<td>8.4</td>
<td>12.2</td>
<td>12.8</td>
<td>5.5</td>
<td>5.8</td>
<td>3.8</td>
<td>2.9</td>
<td>3.8</td>
<td>5.2</td>
<td>5.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jorenby et al. [41]</td>
<td>Varenicline 1 mg bid</td>
<td>340</td>
<td>7.4</td>
<td>7.9</td>
<td>21.2</td>
<td>5.9</td>
<td>7.4</td>
<td>8.6</td>
<td>2.1</td>
<td>3.8</td>
<td>2.9</td>
<td>6.8</td>
<td>2.1</td>
<td>5.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bupropion SR 150 mg bid</td>
<td>340</td>
<td>9.7</td>
<td>12.6</td>
<td>12.4</td>
<td>3.5</td>
<td>7.1</td>
<td>1.5</td>
<td>2.4</td>
<td>8.5</td>
<td>3.5</td>
<td>2.8</td>
<td>1.8</td>
<td>3.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>340</td>
<td>9.7</td>
<td>12.6</td>
<td>12.4</td>
<td>3.5</td>
<td>7.1</td>
<td>1.5</td>
<td>2.4</td>
<td>8.5</td>
<td>3.5</td>
<td>2.8</td>
<td>1.8</td>
<td>3.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aubin et al. [57]</td>
<td>Varenicline 1 mg bid</td>
<td>370</td>
<td>37.2</td>
<td>19.1</td>
<td>21.3</td>
<td>11.7</td>
<td>7.4</td>
<td>8.2</td>
<td>5.9</td>
<td>5.6</td>
<td>6.1</td>
<td>8.4</td>
<td>5.9</td>
<td>5.9</td>
<td>5.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NRT 21 mg/day</td>
<td>370</td>
<td>8.7</td>
<td>9.7</td>
<td>19.2</td>
<td>8.4</td>
<td>3.5</td>
<td>2.4</td>
<td>1.4</td>
<td>2.4</td>
<td>1.1</td>
<td>1.4</td>
<td>2.7</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tonstad et al. [68]</td>
<td>Initial 12 weeks, open label</td>
<td>Varenicline 1 mg bid</td>
<td>1927</td>
<td>33.5</td>
<td>15.8</td>
<td>19.6</td>
<td>14.3</td>
<td>8.7</td>
<td>12.1</td>
<td>8.4</td>
<td>6.9</td>
<td>7.5</td>
<td>5.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12-week extended treatment, randomised</td>
<td>Varenicline 1 mg bid</td>
<td>602</td>
<td>1.2</td>
<td>2.8</td>
<td>2.7</td>
<td>1.0</td>
<td>0.0</td>
<td>0.3</td>
<td>1.5</td>
<td>1.5</td>
<td>4.8</td>
<td>2.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>604</td>
<td>0.7</td>
<td>2.0</td>
<td>2.8</td>
<td>0.0</td>
<td>0.5</td>
<td>0.0</td>
<td>1.8</td>
<td>1.0</td>
<td>6.3</td>
<td>4.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tsai et al. [69]</td>
<td>Varenicline 1 mg bid</td>
<td>126</td>
<td>43.7</td>
<td>15.1</td>
<td>5.6</td>
<td>7.1</td>
<td>5.6</td>
<td>7.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>124</td>
<td>11.3</td>
<td>13.7</td>
<td>0.8</td>
<td>2.4</td>
<td>6.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang et al. [70]</td>
<td>Varenicline 1 mg bid</td>
<td>165</td>
<td>29.1</td>
<td>5.5</td>
<td>6.1</td>
<td>14.5</td>
<td>5.5</td>
<td>9.1</td>
<td>6.1</td>
<td>7.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>168</td>
<td>11.3</td>
<td>4.2</td>
<td>3.9</td>
<td>10.7</td>
<td>5.4</td>
<td>7.7</td>
<td>3.0</td>
<td>2.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura et al. [71]</td>
<td>Varenicline 1 mg bid</td>
<td>155</td>
<td>24.4</td>
<td>10.3</td>
<td>7.7</td>
<td>35.9</td>
<td>5.6</td>
<td>7.7</td>
<td>5.8</td>
<td>3.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 0.5 mg bid</td>
<td>155</td>
<td>9.7</td>
<td>11.6</td>
<td>7.7</td>
<td>51.0</td>
<td>4.5</td>
<td>7.4</td>
<td>3.2</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 0.25 mg bid</td>
<td>153</td>
<td>7.2</td>
<td>10.5</td>
<td>8.5</td>
<td>43.1</td>
<td>8.5</td>
<td>2.0</td>
<td>4.6</td>
<td>5.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>154</td>
<td>7.8</td>
<td>2.6</td>
<td>5.2</td>
<td>38.3</td>
<td>9.6</td>
<td>6.5</td>
<td>5.8</td>
<td>6.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Williams et al., 52 weeks [10]</td>
<td>Varenicline 1 mg bid</td>
<td>251</td>
<td>40.2</td>
<td>19.1</td>
<td>22.7</td>
<td>7.6</td>
<td>12.4</td>
<td>12.4</td>
<td>13.1</td>
<td>8.8</td>
<td>10.8</td>
<td>5.2</td>
<td>3.2</td>
<td>6.0</td>
<td>6.8</td>
<td>7.2</td>
<td>6.4</td>
<td>8.8</td>
<td>8.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>126</td>
<td>7.9</td>
<td>9.3</td>
<td>7.1</td>
<td>4.8</td>
<td>7.1</td>
<td>9.5</td>
<td>2.4</td>
<td>1.6</td>
<td>2.4</td>
<td>6.3</td>
<td>4.6</td>
<td>6.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nauru et al., flexible dosing [32]</td>
<td>Varenicline 0.5-2.0 mg/day</td>
<td>157</td>
<td>13.4</td>
<td>15.9</td>
<td>21.7</td>
<td>6.4</td>
<td>5.1</td>
<td>5.1</td>
<td>16.9</td>
<td>7.0</td>
<td>5.1</td>
<td>5.7</td>
<td>5.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>155</td>
<td>5.2</td>
<td>12.9</td>
<td>11.0</td>
<td>1.9</td>
<td>1.3</td>
<td>3.9</td>
<td>9.7</td>
<td>4.5</td>
<td>4.5</td>
<td>1.9</td>
<td>3.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orckien et al.</td>
<td>Varenicline 1.0 mg bid titrated</td>
<td>129</td>
<td>34.9</td>
<td>22.5</td>
<td>37.2</td>
<td>19.4</td>
<td>10.9</td>
<td>10.1</td>
<td>14.7</td>
<td>11.6</td>
<td>9.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 1.0 mg bid nontitrated</td>
<td>124</td>
<td>41.9</td>
<td>24.2</td>
<td>21.8</td>
<td>16.0</td>
<td>10.9</td>
<td>11.3</td>
<td>9.7</td>
<td>13.7</td>
<td>10.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 0.5 mg bid titrated</td>
<td>129</td>
<td>16.3</td>
<td>19.4</td>
<td>20.9</td>
<td>11.6</td>
<td>4.7</td>
<td>8.5</td>
<td>0.2</td>
<td>7.8</td>
<td>5.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 0.5 mg bid nontitrated</td>
<td>124</td>
<td>22.6</td>
<td>27.4</td>
<td>33.9</td>
<td>16.9</td>
<td>6.5</td>
<td>15.3</td>
<td>8.9</td>
<td>16.1</td>
<td>5.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>121</td>
<td>14.0</td>
<td>17.4</td>
<td>11.6</td>
<td>5.0</td>
<td>2.5</td>
<td>5.8</td>
<td>7.4</td>
<td>1.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nides et al., 7 weeks [37]</td>
<td>Varenicline 1 mg bid</td>
<td>125</td>
<td>52.0</td>
<td>24.0</td>
<td>35.2</td>
<td>15.2</td>
<td>5.6</td>
<td>8.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 1 mg qd</td>
<td>126</td>
<td>37.3</td>
<td>27.0</td>
<td>27.0</td>
<td>11.1</td>
<td>6.3</td>
<td>6.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varenicline 0.3 mg qd</td>
<td>126</td>
<td>17.5</td>
<td>27.0</td>
<td>19.8</td>
<td>7.9</td>
<td>6.3</td>
<td>7.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bupropion SR 150 mg bid</td>
<td>126</td>
<td>21.4</td>
<td>30.2</td>
<td>45.2</td>
<td>11.9</td>
<td>13.5</td>
<td>11.1</td>
<td>7.1</td>
<td>11.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>123</td>
<td>18.7</td>
<td>26.8</td>
<td>22.0</td>
<td>8.1</td>
<td>4.1</td>
<td>7.3</td>
<td>7.3</td>
<td>9.8</td>
<td>5.7</td>
<td>25.2</td>
<td>8.1</td>
<td>5.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Treatment was for 12 weeks except where otherwise indicated. Each row lists the incidence of adverse events reported in the primary publication for that study. A blank cell indicates no adverse event was reported under that terminology in the publication.

The incidence of an adverse event was reported if ≥5% in the varenicline group and more frequent than in the placebo group.

The incidence of an adverse event was reported if ≥5% in either the varenicline or bupropion SR group and more frequent than in the placebo group.

The incidence of an adverse event was reported if ≥5% in any treatment group.

The incidence of an adverse event in the open-label study was reported if ≥5%. In the double-blind extension, the incidence of an adverse event was reported if ≥5% in the varenicline group and more frequent in the varenicline group than the placebo group.

The incidence of an adverse event was reported if ≥10% in any treatment group, including placebo.

bid = twice daily; Bupropion SR = sustained-release bupropion; qd = once daily

21. Mihalak KB, Carroll Fl, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 2006 Sep; 70(3): 801-5


60. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry 2008 Jun; 165(6): 774


64. Hauben M, Wilson G, Reich L. A preliminary quantitative analysis of the spontaneous reporting of selected adverse events with chantix in the US FDA adverse event reporting system data base. 10th Annual Conference of SRNT Europe; 2008 23-26 September Rome, Italy